The company is planning on adding up to 1.5 million sq. ft. of cGMP distribution space for COVID-19 shipments.
UPS Healthcare, a supply-chain solutions provider for the pharmaceutical and biopharmaceutical industries, announced on June 10, 2020 that it will complete a series of facility expansions to its healthcare-dedicated warehouse and distribution network.
According to a press release, the company is planning on adding up to 1.5 million ft2 of cGMP distribution space for COVID-19 shipments, including good distribution practice (GDP)-compliant spaces opening in central and eastern Europe, cold-chain space near its Worldport facility in Louisville, KY, and a new facility in Shanghai, China. UPS will also add additional cooler and freezer space to its GMP facility in Louisville.
“UPS Healthcare continues to build out a global distribution infrastructure that demonstrates our commitment to the healthcare industry,” said Wes Wheeler, UPS Healthcare president, in the press release. “We will continue to innovate and expand our quality systems throughout our expanded network to further support more complex pharmaceutical and lab testing requirements.”
Source: UPS Healthcare
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.